Premier submitted comments to CMS in response to the proposed rule for the MA and Medicare Prescription Drug Benefit (Part D) Programs for Contract Year 2025. The proposed rule seeks public comment on CMS’ proposals to ensure timely access to care, protect beneficiaries from…
Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (Nasdaq: HSIC), today announced the launch of Henry Schein RISE (Resources, Infection Prevention, Solutions & Support, Education) – a platform designed to provide ambulatory surgery centers (ASCs) with infection prevention resources including access to third-party…
-OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced that its Healthcare division, Spacelabs Healthcare®, has received an order valued at approximately $5 million to provide patient monitoring solutions and related supplies and accessories to a U.S.…
Most comprehensive and ethnically diverse genomic coverage on a high throughput microarray delivers multi-disease and pharmacogenomic research analysis across global populations -Earlier this year, scientists unveiled the first draft of the pangenome, based on full genetic blueprints from 47 people…
Leading US Institutions Launch Innovative Histotripsy Liver Treatment Programs the manufacturer of the non-invasive Edison® histotripsy system, today announced that a patient at the University of Rochester Medical Center had was the first in the world to receive targeted treatment…
a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023. Preliminary Fourth Quarter Revenue and Cash Balance Preliminary Full Year 2023 Revenue and Cash Usage “Our…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024, it closed the previously announced underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”). The offering was priced at $28.50…
ZELSUVMI™ is expected to be commercially available during the second half of 2024 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum…
a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it is finalizing its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy. This announcement comes…
today announced several leadership updates, effective immediately: “We are fortunate to have someone of Tom’s caliber and experience already within CVS Health today and ready to take on the role. His experience in health care is deep and broad, and…
Today CVS Caremark®, a CVS Health® (NYSE: CVS) company, announced the continuation of its efforts to expand adoption of biosimilars. Effective April 1, 2024, Humira® will be removed from our major national commercial template formularies and Humira biosimilars will be covered. Humira…
Elevance Health (NYSE: ELV) today announced that it has entered into an agreement to acquire Paragon Healthcare, Inc., a company specializing in life-saving and life-giving infusible and injectable therapies. For more than 20 years, Paragon Healthcare has provided infusion services…